List view / Grid view
A preclinical study led by VHIO reveals that the MYC inhibitor Omomyc enhances the effectiveness of PARP inhibitors, offering a potential new treatment strategy for patients with drug-resistant triple-negative breast cancer.
A new study has revealed that the enzyme EZH2 triggers abnormal cell division that fuels metastasis, and blocking this enzyme with existing drugs could restore normal cell behaviour to stop cancer from spreading.
Researchers identified variants in three loci that were associated with risk of triple-negative breast cancer.
Cofounder & Chief Scientific Officer of Pheast Therapeutics, Dr Roy Maute, reveals his company’s promising drug candidate and explains why they have focused on their chosen target.
US researchers innovate cancer diagnostics using Kinase Inhibitor Pulldown Assay, or KIPA, to search for proteins they could target to control tumour growth.
This article highlights five of the latest findings revealed using CRISPR that could be used in the development or design of new therapies.
